AI Article Synopsis
- Scientists don't have a standard way to treat people who have both psoriasis and bullous pemphigoid, even though psoriasis can raise the chances of getting the other disease.
- In a case, an elderly patient with psoriasis got both diseases and got better after taking a medicine called dymethylfumarate.
- When dymethylfumarate was stopped due to a side effect, another medicine called risankizumab was given, and the patient didn't have any more problems from the diseases.
Article Abstract
A standardised therapeutic approach to coexistent psoriasis and bullous pemphigoid is lacking, although psoriasis is associated with an increased risk of developing bullous pemphigoid. Here, we report an elderly psoriatic patient who developed a refractory bullous pemphigoid and experienced clearance of both diseases following treatment with dymethylfumarate. Due to lymphopenia, this treatment was stopped and the patient was administered risankizumab without relapses. Dymethylfumarate may be able to inhibit the recruitment of neutrophils and monocytes into the skin. Therefore, thanks to pleiotropic effects, dymethylfumarate could be an effective treatment in psoriatic patients who develop bullous pemphigoid.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460171 | PMC |
| http://dx.doi.org/10.2147/PTT.S417427 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bullous pemphigoid: Investigating the risk of losing functional autonomy in everyday life.
J Eur Acad Dermatol Venereol
February 2025
2nd Dermatology Department, Center of Expertise on AIBD, Papageorgiou General Hospital, Aristotle University School of Medicine, Thessaloniki, Greece.
Associated factors related to production of autoantibodies and dermo-epidermal separation in bullous pemphigoid.
Arch Dermatol Res
January 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, 9 Dongdan 3rd Alley, Beijing, 100730, China.
Bullous pemphigoid (BP) is a debilitating autoimmune skin blistering disease, characterized by the deposition of specific autoantibodies at the dermal-epidermal junction. This leads to an inflammatory cascade involving the activation of complement proteins, mast cell degranulation, immune cell recruitment, and the release of proteases by granulocytes. While several cytokines and signaling pathways have been implicated in the pathogenesis of BP, the precise mechanism behind autoantibody production remains unclear.
View Article and Find Full Text PDFImmunohistochemistry for Immunoglobulin G4 on Paraffin Sections as a Diagnostic Test for Pemphigus.
Am J Dermatopathol
February 2025
Department of Dermatology and Venereology, Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria.
Pemphigus is a group of autoimmune bullous diseases mediated by autoantibodies most often of the immunoglobulin G class, subclasses immunoglobulin G1, and immunoglobulin G4 (IgG4), directed against desmosomal adhesion proteins of keratinocytes. This study aimed to evaluate IgG4 immunoreactivity on paraffin sections using immunohistochemistry in patients with pemphigus as a diagnostic test. Fifty formalin-fixed paraffin-embedded specimens from patients with pemphigus were selected.
View Article and Find Full Text PDFBullous pemphigoid with anti-desmoglein antibodies: An incident of coincidence or not?
Chin Med J (Engl)
January 2025
Hospital for Skin Diseases, Shandong First Medical University, Jinan, Shandong 250061, China.
Concurrent presentation of acute lymphoblastic leukemia and bullous pemphigoid: a rare case report.
Oxf Med Case Reports
January 2025
Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Jalan Perintis Kemerdekaan KM. 11, Makassar, South Sulawesi 90245, Indonesia.
Historically, adolescents and young adults diagnosed with acute lymphoblastic leukemia (ALL) have faced lower survival rates compared to children with the same illness. Bullous pemphigoid (BP), a rare autoimmune skin disorder, poses unique challenges when occurring alongside hematologic malignancies. A 23-year-old male with ALL-L1 diagnosis who developed bullous pemphigoid in this report.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!